FREE TREATMENT REPORT

See ratings and reviews when you sign up for an account.

A Phase 2, Double-masked, Randomized, Active-controlled, Crossover Study Assessing the Safety and Ocular Hypotensive Efficacy of AR-12286 or Timolol Added to Patients With Elevated Intraocular Pressure Currently Using Latanoprost

This study is currently Active, not recruiting

October 2011 By Aerie Pharmaceuticals

First Recieved on February 18, 2011

Last Updated on October 10, 2011

Sponsor: Aerie Pharmaceuticals
Collaborators:
Information provided by: Aerie Pharmaceuticals
Identifier: NCT01302249

Purpose

This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).

Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Eligibility

Ages Eligible for Study:18 Years
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No
Criteria

Inclusion Criteria: - 18 years of age or greater. - Diagnosis of open angle glaucoma (OAG) or ocular hypertension (OHT). - Currently using prostaglandin analogue (monotherapy or combination therapy) O.U. ? 1 month at time of study entry (first qualification visit) in study eye(s). - Qualification Visit 1 (Screening) IOP at 16:00 hrs: PG monotherapy patients: ? 18 mm Hg; Combination therapy patients: >= 16 mm Hg. Qualification Visit 2 (post latanoprost run-in) IOP ? 20 mm Hg at 08:00 hrs and 10:00 hrs, IOP ? 18 mm Hg at 16:00 hrs in study eye(s). (Note: combination therapy may include any combination of topical ocular hypotensive agents). - Corrected visual acuity in each eye +1.0 logMAR or better by ETDRS in each eye (equivalent to 20/200). - Able and willing to give signed informed consent and follow study instructions Exclusion Criteria: In either eye: - Previously randomized to treatment in a clinical study of AR-12286. - Intraocular pressure > 36 mm Hg. - History of acute angle-closure glaucoma, or closed or narrow angle upon gonioscopy - Known hypersensitivity or contraindication to timolol maleate ophthalmic solution, or any component of the formulation (benzalkonium chloride, etc.), or to topical anesthetics, including history of conjunctival hyperemia with topical latanoprost of severity greater than 1 on a 0-3 scale. - Ocular trauma within the past six months, or ocular surgery or laser treatment within the past three months. - Contact lens wear within 30 minutes of instillation of study medication. - PG monotherapy patients: Ocular hypotensive medication (other than prostaglandin) within 4 weeks of Visit 0 (Study entry, first qualification visit). Combination therapy patients: Ocular hypotensive medication (other than prostaglandin and current additional agent) within 4 weeks of Visit 0 (Study entry, first qualification visit). - Conjunctival hyperemia of grade 2+ or greater at Visit 1. - Any other ocular medication within 4 weeks of Visit 1 with the exception of lubricating drops for dry eye (which may be used throughout the study). - Clinically significant ocular disease (e.g. corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that treatment with only latanoprost for two periods of up to 4 weeks is not judged safe (e.g., advanced glaucomatous optic nerve head or visual field loss). - Any abnormality preventing reliable applanation tonometry of either eye. In study eye(s): - Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure. Note: Previous laser peripheral iridotomy is acceptable. - Previous glaucoma intraocular surgery or laser procedures. - Refractive surgery (e.g., radial keratotomy, PRK, LASIK, etc.). - Central corneal thickness greater than 600 ?. Systemic: - Known bronchial asthma (history or current), severe chronic obstructive pulmonary disease, sinus bradycardia, second or third degree atrioventricular block or overt cardiac failure. - Clinically significant abnormalities in laboratory tests at screening, recognizing that subjects are not fasting at the time of drawing blood. - Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, cardiovascular or endocrine disorders) which might interfere with the study. - Participation in any investigational study within the past 30 days. - Changes of systemic medication that could have a substantial effect on IOP 4 weeks prior to screening, or anticipated during the study. - Due to status of preclinical safety program, women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study.

Investigators

Locations

  • David Silverstone, M.D.

    New Haven, Connecticut 06510 United States

  • Coastal Research Associates, LLC

    Roswell, Georgia 30076 United States

  • Heart of America Eye Care, P.A.

    Shawnee Mission, Kansas 66204 United States

  • Taustine Eye Center

    Louisville, Kentucky 40217 United States

  • Alan L Robin, M.D.

    Baltimore, Maryland 21209 United States

  • Comprehensive Eye Care

    St Louis, Missouri 63090 United States

  • Rochester Ophthalmology Group

    Rochester, New York 14618 United States

  • Glaucoma Consultants of the Capital Region

    Slingerlands, New York 12159 United States

  • Charlotte Eye Ear Nose and Throat

    Charlotte, North Carolina 28210 United States

  • Thomas K. Mundorf, M.D.

    Charlotte, North Carolina 28204 United States

  • The Eye Institute

    Tulsa, Oklahoma 74104 United States

  • Wills Eye Hospital

    Philadelphia, Pennsylvania 19107 United States

  • Black Hills Regional Eye Institute

    Rapid City, South Dakota 57701 United States

  • Cataract & Glaucoma Center

    El Paso, Texas 79902 United States

  • Stacy R. Smith, M.D.

    Salt Lake City, Utah 84117 United States

advertisement
V2012.311.925.327
Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.